Topical vs Systemic Therapy in Psoriasis: Escalating Wisely in the Biologic Era Review Abstract Purpose: This review examines how clinicians should decide among optimized topical therapy, phototherapy, oral systemic treatment, and biologic therapy in plaque psoriasis. Methodology: Review of recent clinical guidelines, FDA prescribing information,
Tag: psoriatic arthritis
Obesity, Metabolic Syndrome, and ‘Difficult-to-Treat’ Psoriatic Arthritis: Is Inflammation Only Half the Story?
Obesity, Metabolic Syndrome, and ‘Difficult-to-Treat’ Psoriatic Arthritis Is Inflammation Only Half the Story Review Abstract Psoriatic arthritis (PsA) is a chronic, immune mediated inflammatory musculoskeletal disease that affects a substantial proportion of individuals with psoriasis. Characterized by peripheral arthritis, enthesitis, dactylitis, axial involvement, and progressive joint damage, PsA is associated
Guselkumab Provides Relief For Patients Who Suffer With Psoriasis
Guselkumab Provides Relief For Patients Who Suffer With Psoriasis Overview A 52-week postmarketing surveillance study was launched to assess the safety and effectiveness of guselkumab, a human monoclonal antibody targeting the interleukin-23 subunit p19, in Japanese patients diagnosed with psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis, and erythrodermic psoriasis in real-world clinical
Golimumab Compliance In Long-Term Arthritis Treatment
Golimumab Compliance In Long-Term Arthritis Treatment STUDY BACKGROUND Biological and targeted synthetic disease-modifying antirheumatic drugs (bDMARDs and tsDMARDs) are the cornerstones in treating inflammatory arthritides such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (SpA). Tumor necrosis factor-alpha (TNFα) inhibitors, including adalimumab, infliximab and golimumab are the most commonly prescribed
